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In vitro and in vivo laboratory studies and clinical data have gener-
ated ample evidence that neovascularization supports solid tumour
viability and growth (Folkman, 1995). Along this line, a recent
paper from Perez-Atayde et al (1997) has suggested that angio-
genesis might also play a pivotal role in human leukaemia. In fact,
these authors have found a median of 42 vessels per 2003 field in
bone marrow (BM) biopsies from paediatric acute lymphoblastic
leukaemia (ALL) patients compared to a median of 6 vessels in
normal controls. Differences between relapsed and non-relapsed
patients were not significant, and chemotherapy did not decrease
the number of vessels per field. Consistent with these data,
increased levels of the endothelial cell mitogenic molecule basic
fibroblast growth factor (bFGF) have been reported in the urine of
paediatric ALL patients compared to controls. Again, chemo-
therapy did not significantly decrease bFGF concentration in the
patients’ urine. More indirect evidence of neovascularization in
leukaemia comes from the observation that vascular endothelial
growth factor (VEGF) is expressed by acute myeloid leukaemia
(AML) cells and leukaemic cell lines and possibly act as a
paracrine growth factor in the development of myeloid leukaemia
(Fiedler et al, 1997). Moreover, it has been proposed that angio-
genesis and VEGF could play a cardinal role also in lymphoma
(Foss et al, 1997; Salven et al, 1997) and myeloma (Vacca et al,
1994) development. We were interested in determining whether
conversion of normal cells into preleukaemic-myelodysplastic
(MDS), and ultimately leukaemic cells is a multistep process
requiring the generation of new blood vessels. To this aim, we
evaluated microvessel density (MVD) and VEGF expression in
BM biopsies from healthy controls, infectious disease (ID), MDS,
AML and myeloproliferative disorder (MPD) patients.
MATERIALS AND METHODS
We evaluated 133 paraffin-embedded BM biopsies collected from
1988 to 1998. BM biopsies were from 14 controls (solid cancer or
Hodgkin’s disease patients undergoing staging or follow-up and
found to be free of neoplasia at histological examination), five ID,
85 MDS, 15 AML and 14 MPD patients. Among MDS patients,
the median age was 67 years (range 26–86), 34% patients were
female and 66% male. MDS, AML or MPD diagnosis was made
according to FAB classification by means of BM aspirate stained
with May–Grunewald–Giemsa and trephine biopsy stained with
haematoxylin–eosin, Gomori and Giemsa. Ninety-four biopsies
were fixed in B5, decalcified by EDTA (Mielodec, Bio-Optica,
Milan, Italy) and embedded in paraffin in Milan, 39 were fixed in
10% buffered formalin, decalcified in 10% formic acid and
embedded in paraffin in London. The immunohistochemical
analysis was made by means of the avidin–biotin peroxidase
complex (ABC) method using the 3,3¢-diaminobenzidine tetra-
hydrochloride chromogen. The 4-mm-thick sections were immuno–-
stained with the following monoclonal antibodies: CD34-reactive
QBEnd/10 (1:10 working concentration, Signet Laboratories Inc.,
Dedham, MA, USA), CD31-reactive 1A10 (1:50 working concen-
tration, Novocastra Laboratories Ltd, Newcastle upon Tyne, UK),
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VEGF-reactive Ab-3 (1:100 working concentration, Oncogene
Research Products, Cambridge, MA, USA). Slides were slightly
counterstained with haematoxylin. For antigen retrieval, the slides
were placed in a 0.1 M citrate buffer at pH 6.0 (VEGF and CD31),
or in a 0.001 M EDTA buffer at pH 8.0 (CD34) and underwent
three (VEGF and CD31) or four (CD34) 5-min 780W cycles at 90°
in a microwave oven. According to the manufacturer, biopsies
from fetal kidneys and hormone-secreting prostate cancer patients
were evaluated as VEGF-positive controls. The substitution of the
primary antibody with non-immune mouse serum was used as
negative control. MVD enumeration was made according to
Perez-Atayde et al (1997): in each sample a mean of 12 ± 7 micro-
scopic fields (median 12, range 3–47) was evaluated at 2503
magnification, each field representing an area of 0.72 mm2. Any
brown staining endothelial cell or endothelial cell cluster that was
clearly separated from adjacent microvessels was considered a
single, countable microvessel and vessel lumens were not a
prerequisite to define a structure as a microvessel.
Immunostaining of blasts and arterioles, clearly identifiable by the
round shape and the presence of a central nucleus with one or more
nucleoli, and by the presence of the media layer, were not counted.
For each case, the median value of vessels and the field with the
highest number of vessels (‘hot spot’) were recorded. Two readers
evaluated slides in a blind fashion.
Statistical comparisons were performed using the linear regres-
sion analysis, the t-test, analysis of variance (ANOVA) and
Student–Neumann–Keuls test in paired studies and the non-para-
metric analyses of Mann–Whitney, Wilcoxon and Kruskal–Wallis
in non-paired studies. Values of P lower than 0.05 were considered
as statistically significant.
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Figure 1 Examples of immunohistochemical results, 253 original magnification if not otherwise indicated, haematoxylin counterstain. CD31 and CD34
expression in the same field of a MPD BM biopsy. CD31 was expressed in a very large population of BM cells, including megakaryocytes and myeloid cells (A).
Thus, in most cases, accurate MVD enumeration was not feasible. Conversely, CD34 was expressed only by haematopoietic progenitor and endothelial cells,
thus allowing a more accurate MVD evaluation (B). MVD in representative BM biopsies from healthy controls (C), MDS (D–H), AML (I) and MPD (CML) patients
(J). VEGF expression in representative BM biopsies from MDS patients. VEGF expression was limited to the cytoplasm of megakaryocytes (some of which
indicated by arrows in K), with higher intensity along the cell membrane (L, 633 original magnification)1400 G Pruneri et al
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RESULTS
Best immunohistochemical results were obtained with anti-CD34
monoclonal antibody QBEnd/10, which depicted endothelial cells
and a variable number of blasts. With this antibody, MVD intra-
reader variability was found to be 14 ± 10% (r = 0.879), thus
indicating good reproducibility. By contrast, anti-CD31 invariably
immunostained myeloid, lymphoid cells and megakaryocytes
besides vessels, thus making difficult the microvessels count
(Figure 1 A, B). Therefore, only the results obtained with the
QBEnd/10 antibody are given (Figure 1 B–J). In three out of 85
MDS cases, CD34+ BM blast frequency was so high that MVD
evaluation by means of CD34+ vessel enumeration was not
feasible. Consequently, throughout the study we report data from
82 MDS cases. As shown in Table 1, MVD and hot spots were
similar in controls and ID, significantly higher in MDS than in
controls and ID, significantly lower in MDS than in AML and
MPD (P < 0.001 by ANOVA and Student–Neumann–Keuls test).
Among FAB-related MDS subsets, MVD was significantly higher
in the RAEB-t, CMML and fibrosis subsets compared to RA,
RARS and RAEB subsets (P = 0.008). No significant differences
were found between the RAEB-t, CMML and fibrosis MDS-
related subsets and AML patients. A detailed evaluation of the
international prognostic scoring system (IPSS; Greenberg et al,
1997) was available in 29 out of 82 evaluated MDS patients, and
in this subset MVD did not correlate significantly with age,
gender, presence of chromosome abnormality and PLT count,
whereas a weak trend indicated a higher MVD in patients with
higher blast frequency, white blood cell (WBC) count and lower
haemaglobin (Hb) levels (r = 0.20, 0.28 and 0.29 respectively).
Detailed data about progression to AML were available for 22
patients. In this small group, MVD differences between patients
who developed AML and patients who had stable MDS were not
significant.
In normal controls the vessels showed a straight shape (Figure
1C), whereas in MDS, AML and MPD there were basically three
morphological types of vessels: large vessels with visible lumina
and very irregular, branching shape (Figure 1 D, E), sinusoids-like
vessels (Figure 1B), and small vessels without discernible lumina
(Figure 1 I, J), which have been defined ‘endothelial sprouts’ by
Perez-Atayde et al (1997). Whereas these morphological variants
were usually detectable in the same case, the first type predomi-
nated in MDS, the second in MPD and the third in AML. VEGF
expression was usually found in the cytoplasm of megakaryocytes
and histiocytes in normal controls, MDS and MPD, whereas the
blast compartment was usually unreactive (Figure 1 K, L). In
particular, among AML patients we have observed few scattering
VEGF expressing blasts representing less than 1% of the total
blast population.
DISCUSSION
The seminal observation by Perez-Atayde et al (1997) of neovas-
cularization in ALL BM environment prompted us to study MVD
in preleukaemia-MDS BM biopsies. In fact, it has been suggested
in the past that the growth of primary solid tumours is strictly
dependent on their ability to induce angiogenesis from the
surrounding vasculature, so that tumour progression, including
invasion and metastasis, involves two different phases, prevas-
cular and vascular (Gimbrone et al, 1972; Folkman, 1990). Our
finding that MDS has intermediate MVD levels between controls
and AML might suggest a correlation between angiogenesis and
progression to leukaemia, and it seems unlikely that increased
MVD was solely due to hypercellularity. In fact, MVD observed in
five cases with reactive hypercellular BM was comparable to that
of normocellular control trephines. The correlation between angio-
genesis and progression to leukaemia is further supported by the
observation that MDS patients with enhanced blasts accumulation
and, in particular, the RAEB-t in addition to CMML and fibrosis
subsets, show an increased MVD. Regarding the CMML and
fibrosis MDS subsets, our finding of an increased MVD compared
to RA, RARS and RAEB subsets correlates well with recent
observations of VEGF generation by solid tumour-associated
macrophages (Lewis et al, 1995) and fibroblasts (Foss et al, 1997;
Fukumura et al, 1998). In fact, VEGF is currently considered the
most relevant and the only endothelium-specific one among
already known endothelial cell mitogenic factors, and it seems to
be involved in the vascular phase of many different neoplastic
diseases (Ferrara and Davis-Smyth, 1997). Given that a recent
report (Fiedler et al, 1997) has demonstrated VEGF mRNA gener-
ation from AML BM cells and leukaemic cell lines and VEGF
protein generation in AML cell culture, one can speculate that
leukaemic or even preleukaemic blasts might be among the prin-
cipal providers of VEGF in the BM environment. On the other
hand, we have evaluated BM biopsies from controls, ID, MDS
AML and MPD and have found that VEGF expression is particu-
larly high in megakaryocyes and, on some occasions, in
macrophages, but markedly less relevant or otherwise below the
detection limit of our procedure in MDS and AML blasts. This
finding is in accordance with previous reports (Mohle et al, 1997;
Banks et al, 1998) indicating relevant VEGF expression along the
megakaryocytic differentiation pathway, and also suggests that
MDS or leukaemic blasts might not produce clinically relevant
amounts of VEGF. Interestingly, in one particular MDS case a
remarkably high frequency of VEGF-positive megakaryocytes
was associated with high median MVD (26.5) and hot spot (40).
Thus, we are currently evaluating whether megakaryocytes play a
crucial role in MDS-related angiogenesis.
In a very recent paper, Fukumura et al (1998) have reported
about transgenic mice expressing the green fluorescent protein
(GFP) under the control of the promoter for VEGF. In this elegant
model, spontaneous tumours induced by oncogene expression
show strong stromal, but not tumour, expression of GFP, and the
predominant GFP-positive cells are fibroblasts. This finding
implies that the VEGF promoter might be activated by the tumour
Table 1 Mean (± 1 s.d.) MVD and hot spots in control, ID, MDS, AML and
MPD patients
n MVD (per 2503 field) Hot spots
Controls 14 6 ± 2 12 ± 4
ID 5 10 ± 8 19 ± 13
MDS (overall) 82 21 ± 9a 34 ± 13a
RA 14 21 ± 7 33 ± 9
RARS 13 19 ± 8 35 ± 17
RAEB 35 19 ± 8 30 ± 10
RAEB-t 11 28 ± 12 41 ± 17
CMML 4 28 ± 5 39 ± 4
Fibrosis 4 29 ± 8 43 ± 14
AML 15 30 ± 12a,b 43 ± 19a,b
MPD 14 40 ± 14a,b,c 57 ± 19a,b,c
aP < 0.05 vs controls and ID, bP < 0.05 vs MDS, cP < 0.05 vs AML, by
analysis of variance and Student–Neumann–Keuls test.Angiogenesis in myelodysplastic syndromes 1401
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microenvironment, and suggests a crucial role for stromal cell
collaboration in tumour angiogenesis. In this context, the evalua-
tion of the angiogenic potential of BM stromal cells from MDS,
AML and MPD patients remains a future challenge. We are
currently evaluating VEGF receptors expression and the genera-
tion of other endothelial cell mitogenic factors among different
BM cells of MDS, AML and MPD patients to gain more insight
into the steps from normal to leukaemic BM microenvironment.
Although the clinical and prognostic relevance of neovascular-
ization in MDS, AML and MPD remains to be fully evaluated,
different clinical observations have already indicated that MVD
(Weidner et al, 1991; Graham et al, 1994; Vacca et al, 1994;
Fernandez-Acernero et al, 1998), bFGF (Nguyen et al, 1994)
and/or VEGF (Salven et al, 1997; Linderholm et al, 1998) levels
correlate well with tumour staging and outcome in a number of
malignancies. In this context, neoangiogenesis in haematological
neoplastic diseases is of particular interest, because resting
endothelial cells are known to generate stem cell factor
(Yamaguchi et al, 1996) and Flt3-ligand (Solanilla et al, 1998)
and VEGF-stimulated endothelial cells produce granulocyte–
macrophage colony-stimulating factor (GM-CSF; Fiedler et al,
1997). These cytokines, in turn, act as growth factors for
haematopoietic progenitors and possibly for neoplastic blasts. In
conclusion, our data support an important role of neo angiogenesis
in MDS, AML and MPD. Recent data obtained in animal models
have demonstrated that anti-angiogenic therapy is highly
promising in different experimental neoplastic diseases (Folkman,
1995; Bohem et al, 1997). However, anti-angiogenic therapy may
not be able to induce tumour regression but could inhibit further
growth by a mechanism of ‘tumour stabilization’ (Harris, 1997).
In this frame of reference, it would be interesting not only
to evaluate in experimental leukaemia models the effect of 
anti-angiogenic drugs, alone or in combination with established
chemotherapy regimens, but also whatever anti-angiogenic treat-
ment could have a role in delaying or even preventing disease
progression in MDS patients.
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